Corvus Pharmaceuticals (CRVS) to Release Quarterly Earnings on Thursday

Corvus Pharmaceuticals (NASDAQ:CRVS) is expected to be issuing its Q4 2025 results after the market closes on Thursday, March 12th. Analysts expect the company to announce earnings of ($0.14) per share for the quarter. Individuals are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, March 12, 2026 at 4:30 PM ET.

Corvus Pharmaceuticals Stock Up 0.6%

Corvus Pharmaceuticals stock opened at $15.89 on Tuesday. The business has a 50-day simple moving average of $15.76 and a two-hundred day simple moving average of $10.30. The company has a market cap of $1.33 billion, a P/E ratio of -29.98 and a beta of 0.79. Corvus Pharmaceuticals has a 52-week low of $2.54 and a 52-week high of $26.95.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in CRVS. Quarry LP purchased a new stake in Corvus Pharmaceuticals during the 3rd quarter valued at approximately $27,000. Russell Investments Group Ltd. bought a new position in shares of Corvus Pharmaceuticals during the third quarter worth $49,000. Sender Co & Partners Inc. bought a new position in shares of Corvus Pharmaceuticals during the second quarter worth $52,000. Bayesian Capital Management LP purchased a new position in Corvus Pharmaceuticals during the second quarter valued at $70,000. Finally, The Manufacturers Life Insurance Company bought a new stake in Corvus Pharmaceuticals in the 2nd quarter valued at $76,000. 46.64% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Corvus Pharmaceuticals in a report on Wednesday, January 21st. HC Wainwright upped their target price on shares of Corvus Pharmaceuticals from $11.00 to $27.00 and gave the company a “buy” rating in a report on Tuesday, January 20th. Oppenheimer increased their price target on shares of Corvus Pharmaceuticals from $15.00 to $32.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 21st. Mizuho set a $30.00 price objective on shares of Corvus Pharmaceuticals in a research report on Thursday, January 29th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Corvus Pharmaceuticals in a research note on Thursday, December 11th. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $31.80.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immuno-oncology therapies. The company’s research efforts are centered on harnessing both the innate and adaptive immune systems to counteract tumor-driven immunosuppression. By targeting key pathways that regulate immune cell function, Corvus aims to create novel agents that can be combined with existing cancer treatments to improve patient outcomes.

Corvus’s lead pipeline candidates include small-molecule and antibody therapies designed to inhibit the adenosine pathway, a known mediator of tumor immune escape.